**Supplementary Table 5. The improvement in ascites and hepatic encephalopathy after treatment for 24 weeks**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Variable** |  | **Placebo group (***n=*62) | **YGJ group (***n=*61) | ***p-*value** |
| Ascites, *n* (%) | None | 35 (56.5) | 47 (77.0) | 0.024 |
|  | Mild | 14 (22.5) | 10 (16.4) |  |
|  | Moderate to severe | 13 (21.0) | 4 (6.6) |  |
| HE, *n* (%) | None | 59 (95.2) | 60 (98.4) | 0.422 |
|  | Stage 1–2  | 2 (3.2) | 1 (1.6) |  |
|  | Stage 3–4  | 1 (1.6) | 0 |  |

HE, hepatic encephalopathy.